Patents Assigned to Chord Therapeutics S.a.r.l.
  • Use of cladribine for treating autoimmune inflammatory disease
    Patent number: 10350231
    Abstract: 2-Chloro-2?-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof may be used in the treatment or amelioration of neuromyelitis optica, hereinafter referred to as NMO e.g. in patients known to have NMO-IgG seropositivity or in patients optic neuritis, myelitis and at least two of MRI evidence of contiguous spinal cord lesion 3 or more segments in length, onset brain MRI nondiagnostic for multiple sclerosis or NMO-IgG seropositivity.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: July 16, 2019
    Assignee: Chord Therapeutics S.a.r.l.
    Inventors: Arthur Henry Roach, Konrad Rejdak